{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Table 1 footnote references procedures specific to screening sites detailed in Section 8"
      },
      {
        "id": "ref_2",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Referenced for dose modification or discontinuation criteria in risk mitigation strategy"
      },
      {
        "id": "ref_3",
        "name": "Lifestyle Considerations Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.3",
        "sectionTitle": "Lifestyle Considerations",
        "description": "Referenced in Table 5 for participant lifestyle considerations"
      },
      {
        "id": "ref_4",
        "name": "Contraceptive Guidance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Referenced for contraceptive methods and pregnancy information collection"
      },
      {
        "id": "ref_5",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Referenced for list of clinical laboratory tests to be performed"
      },
      {
        "id": "ref_6",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures",
        "description": "Referenced for recording, evaluating, follow-up, and reporting AEs and SAEs"
      },
      {
        "id": "ref_7",
        "name": "Discontinuation Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal",
        "description": "Referenced for QTc withdrawal criteria and additional QTc readings"
      },
      {
        "id": "ref_8",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Referenced for potential risks and mitigation measures due to COVID-19 vaccine"
      },
      {
        "id": "ref_9",
        "name": "Inclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Referenced for contraceptive start times according to method used"
      },
      {
        "id": "ref_10",
        "name": "Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Referenced for blood donation restrictions prior to screening"
      },
      {
        "id": "ref_11",
        "name": "Lost to Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Referenced for definition of lost to follow-up in SAE follow-up procedures"
      },
      {
        "id": "ref_12",
        "name": "Pregnancy Section Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Referenced for pregnancy or planned pregnancy as discontinuation criteria"
      },
      {
        "id": "ref_13",
        "name": "Genetics Section Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Referenced for retained sample not being used for genetic testing"
      },
      {
        "id": "ref_14",
        "name": "Pharmacodynamics Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Referenced for details of copper and ceruloplasmin measurements"
      },
      {
        "id": "ref_15",
        "name": "Copper Balance Measurements Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Referenced for details of copper measured in food, drink, urine, and feces"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Procedures specific to screening sites (only in the US) detailed in Section 8",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities (SoA), Table 1",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigator's Brochure; PK = pharmacokinetics; WD = Wilson disease",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_4",
        "text": "ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_5",
        "text": "Total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Pharmacokinetic Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol"
      },
      {
        "id": "ver_2",
        "versionNumber": "1.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Protocol Amendment 1",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Protocol Amendment 2",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "3.0",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Protocol Amendment 3",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "3.1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 (US) - Substantial amendment to clarify study procedures occurring across different sites in the US to facilitate participant recruitment and lessen inconvenience for participants",
        "amendmentNumber": "Amendment 3.1 (US)"
      }
    ],
    "summary": {
      "referenceCount": 15,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}